Explanipedia

Comparative efficacy and safety of anakinra and canakinumab in patients with <span>VEXAS</span> syndrome – an international multicenter study Open

Tali Eviatar, Dafne Capelusnik, Corrado Campochiaro, Valentin Lacombe, Vincent Jachiet , et al. · 2025

Objectives The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS syndrome. Methods This multicenter international study includes VEXAS patien…

OP0287 HETEROGENEITY OF THE CLINICAL PRESENTATION IN VEXAS SYNDROME: INSIGHTS FROM 318 CASES FROM THE FRENCH VEXAS STUDY GROUP (FRENVEX). Open

S. Georgin-Lavialle, B. Terrier, Vincent Jachiet, R. Bourguiba, K. Olivier , et al. · 2025

Efficacy of erythroid‐stimulating agent and luspatercept in VEXAS syndrome: A multicenter retrospective study by the FRENVEX group Open

Maël Heiblig, Vincent Jachiet, Jérôme Hadjadj, Lin‐Pierre Zhao, Thibault Comont , et al. · 2025

POS0383 IL-1 INHIBITION IN PATIENTS WITH VEXAS SYNDROME – A RETROSPECTIVE INTERNATIONAL MULTICENTER STUDY Open

T. Eviatar, Iftach Sagy, Corrado Campochiaro, Valentin Lacombe, Vincent Jachiet , et al. · 2025

Correction: Neurological manifestations in patients with VEXAS syndrome Open

Charlotte Bert-Marcaz, Étienne Fortanier, Antoine Briantais, B. Faucher, R. Bourguiba , et al. · 2025

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX Open

Vincent Jachiet, Olivier Kosmider, Maxime Beydon, Jérôme Hadjadj, Lin‐Pierre Zhao , et al. · 2025

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a severe monogenic disorder caused by somatic mutations in ubiquitin-like modifier activating enzyme 1 (UBA1), characterized by inflammation, cytopenias, and freq…

Very long-term remission with azacitidine in VEXAS syndrome Open

Lin‐Pierre Zhao, Vincent Jachiet, Olivier Kosmider, Lise Larcher, Emmanuelle Clappier , et al. · 2025

Not available.

VEXAS anemia is a mosaic erythroblastopenia Open

François Rodrigues, Giulia Hardouin, Sara El Hoss, Aya Ghoul, Emilie‐Fleur Gautier , et al. · 2024

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a recently discovered autoinflammatory disorder linked to somatic mutations in the UBA1 gene, resulting in a profound cytoplasm-restricted defect in ubiquitylation. The di…

A Clinicopathological Description of Kidney Features in VEXAS Syndrome Open

Martin Mathurin, Pierre Hirsch, Vincent Jachiet, Jérôme Hadjadj, G. Le Guenno , et al. · 2024

French protocol for diagnosis and management of Cogan's syndrome Open

Laurent Arnaud, Alexandra Audemard‐Verger, Alexandre Bélot, Boris Bienvenu, C Burillon , et al. · 2024

Bridging the Gap: Registry and Population-Based Perspectives on SOCS1 Insufficiency Open

Jérôme Hadjadj, Anna Franziska Wolfers, Oleg V. Borisov, Derek Hazard, Timothy Ronan Leahy , et al. · 2024

Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: A multicenter retrospective study of 59 cases Open

Ève Zakine, Loula Papageorgiou, R. Bourguiba, A. Mékinian, Benjamin Terrier , et al. · 2022

Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients Open

Mohamed-Yacine Khitri, Alexis F. Guédon, Sophie Georgin‐Lavialle, Benjamin Terrier, David Saadoun , et al. · 2022

Objective A new adult-onset autoinflammatory syndrome has been described, named VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic). We aimed to compare the clinical characteristics, the laboratory features and the outcomes be…

6-Sulfo LacNAc monocytes are quantitatively and functionally disturbed in systemic sclerosis patients Open

Laure Ricard, Déborah Eshagh, Lama Siblany, Frédéric de Vassoigne, Florent Malard , et al. · 2022

Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis, microangiopathy, and autoantibodies. We previously reported that circulating follicular helper T (cTfh) cells are increased in SSc and induce plasmablast differen…

L’infection a SARS-CoV-2 pourrait-elle induire des rhumatismes inflammatoires chroniques ? Une enquête nationale française Open

A. Marty-Ane, Mark R. Sarfati, T. Thomas, Françis Berenbaum, Hubert Marotte , et al. · 2021

Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients* Open

Sophie Georgin‐Lavialle, Benjamin Terrier, Alexis F. Guédon, Maël Heiblig, T. Comont , et al. · 2021

VEXAS syndrome has a large spectrum of organ manifestations and shows different clinical and prognostic profiles. It also raises a potential impact of the identified UBA1 mutation.

Tocilizumab and COVID-19: Timing of administration assessment Open

Quentin Richier, Vincent Jachiet, Vincent Bonnemains, Léo Plaçais, Noémie Abisror , et al. · 2021

Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real‐life study Open

Thibault Comont, Mathieu Meunier, Amina Cherait, Clémence Santana, Thomas Cluzeau , et al. · 2021

Summary Despite a moderate prevalence in low‐risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML), thrombocytopenia remains a risk of severe bleeding and therapeutic options are still limited. There are only a f…

Efficacité du Tocilizumab dans la COVID-19 modérée à sévère : une cohorte française exposé-non exposé Open

Quentin Richier, Vincent Jachiet, Fabrice Carrat, Noémie Abisror, P. Jerome , et al. · 2021

Tocilizumab au cours du COVID-19 : le plus tôt serait le mieux ? Une analyse exploratoire de cohorte Open

Vincent Jachiet, Quentin Richier, Fabrice Carrat, Noémie Abisror, R. Dhôte , et al. · 2021

Inflammatory and Immune Disorders Associated with Myelodysplastic Syndromes Open

Vincent Jachiet, Pierre Fenaux, Anna Sevoyan, Yervand Hakobyan, Lionel Adès , et al. · 2021

Systemic auto-inflammatory or autoimmune diseases (SIADs) develop in up to a quarter of patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). With or without the occurrence of SIADs, the distribution of M…

Acute Myocarditis Revealing Adult-Onset Still’s Disease Open

Raphael M. Cohen, Pascal Nhan, Clément Cholet, Vincent Jachiet, Stéphane Éderhy , et al. · 2021

Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study Open

Marie Péan de Ponfilly-Sotier, Vincent Jachiet, Y. Benhamou, Constance Lahuna, Benoît de Renzis , et al. · 2021

VTE is a common complication in MDS/CMML-associated SIADSs with an increased risk of bleeding when treated by anticoagulants. In the MDS/CMML subgroup, SIADS flares and MDS/CMML progression seem to be prothrombotic risk factors.

Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors Open

Alberto Pïcca, Giulia Berzero, Kévin Bihan, Vincent Jachiet, Édouard Januel , et al. · 2021

Myelitis is a rare but severe complication of ICIs that shows limited response to glucocorticoids. Considering the poor functional outcome associated with longitudinally extensive myelitis, strong and protracted immune therapy combinations…

Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia Open

Vincent Jachiet, Guillaume Moulis, Jérôme Hadjadj, J. Séguier, Kamel Laribi , et al. · 2021

Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are associated with systemic inflammatory or autoimmune diseases in 10-20 % of cases. Among them, immune thrombocytopenia (ITP) has been reported but large studies …

Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study Open

A.L. Roupie, Alexis F. Guédon, Benjamin Terrier, Constance Lahuna, Vincent Jachiet , et al. · 2020

Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib Open

Laure Ricard, Vincent Jachiet, Florent Malard, Yishan Ye, Nicolas Stocker , et al. · 2019

Clinical, imaging, and histological presentations and outcomes of stroke related to sarcoidosis Open

Vincent Jachiet, Raphaël Lhote, Pierre Rufat, M. Pha, Julien Haroche , et al. · 2018

Autoimmune manifestations associated with myelodysplastic syndromes Open

Éric Grignano, Vincent Jachiet, Pierre Fenaux, Lionel Adès, O. Fain , et al. · 2018

Mucosal‐associated Invariant Cells are Deficient in Systemic Sclerosis Open

A. Mékinian, T. Mahévas, Mohamad Mohty, Vincent Jachiet, Sébastien Rivière , et al. · 2017

Systemic sclerosis ( SS c) is an autoimmune disease, characterized by fibrosis of the skin and other organs, vascular impairment and deficient immune responses. Mucosal‐associated invariant T cells ( MAIT ) have been involved in various in…

Vincent Jachiet YOU? Author Swipe